Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2021 Jan 29;110(3):792–803. doi: 10.1016/j.ijrobp.2021.01.033

Table 3.

Summary of grade 3 or higher neurologic toxicities

Early (<6 months post-chemoradiation)
Patient MGMT* methylation status Type Grade Interval from RT (months) Treatment
1 Negative Seizure, worsened hemiparesis, imbalance 3 0.6 Steroids
2 Positive Worsened gait, sensory neglect 3 3 Steroids, bevacizumab
3 Negative Worsened hemiparesis and gait 3 3 Steroids, bevacizumab
4 Positive Seizure, aphasia, worsened hemiparesis 4 During RT Steroids, debulking surgery
Late (>6 months post-chemoradiation)
5 Negative Seizures 3 10 Bevacizumab
6 Positive Hemiparesis, worsened gait and word-finding difficulty 3 17 Bevacizumab
*

MGMT = O6-methylguanine-DNA methyltransferase;

RT=radiation therapy